Sanofi
$630M 13F equity value
16 Holdings
Quarter ended September 30, 2026
The latest 13F on file for Sanofi covers the quarter ended September 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| MGTX | MeiraGTx Holdings plc | 12,197,737 | $134M | 21.3% |
| INBX | Inhibrx Biosciences, Inc. | 1,157,926 | $116M | 18.4% |
| NVAX | Novavax | 6,880,481 | $74M | 11.8% |
| KRSA | Korsana Biosciences | 1,994,011 | $64M | 10.1% |
| ODTX | Odyssey Therapeutics Inc. | 1,990,200 | $44M | 7.0% |
| ANAB | AnaptysBio | 821,917 | $41M | 6.6% |
| AGMB | Agomab Therapeutics NV | 2,783,096 | $31M | 4.9% |
| TRAX | First Tracks Biotherapeutics Inc. | 821,917 | $29M | 4.6% |
| ETRA | Electra Therapeutics Inc | 2,461,948 | $28M | 4.4% |
| ATTO | Attovia Therapeutics Inc | 1,082,855 | $19M | 2.9% |
Track Sanofi's 13F portfolio: $630M in reported holdings, 16 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}